Figure 5: Expression of NKG2D ligands in tumor cells after treatment with decitabine, ionizing radiation (IR), or their combination. | Scientific Reports

Figure 5: Expression of NKG2D ligands in tumor cells after treatment with decitabine, ionizing radiation (IR), or their combination.

From: Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T cells

Figure 5

NKG2D ligand expression in A549 cells (a), HCT-116 cells (b), and HepG2 cells (c) was analyzed by flow cytometry using specific mAbs. Tumor cells were treated with 5 μM decitabine for 24 h then exposed to radiation doses of 8 Gy. Mean fluorescence intensity (MFI) ratio was calculated as MFI with specific mAb/MFI with isotype control mAb (a–c). In the figure, filled white represents the untreated control, filled light gray represents decitabine, filled dark gray represents IR and filled black represents decitabine and IR combination treatment (d). Results are expressed as the average MFI ± SD. Experiments were independently performed from five healthy donors. The assay was performed in triplicated each donor. Statistical significance was determined using a one-way ANOVA. #P < 0.05, ##P < 0.005, ###P < 0.0005 (#DAC 0 versus other groups). **P < 0.005 (*DAC 5 versus other groups). ****P < 0.005 (**IR 8 Gy versus DAC 5 + IR 8 Gy).

Back to article page